Annual report pursuant to Section 13 and 15(d)

Segment Reporting - Summary of Operating Costs and Expenses (Parenthetical) (Details)

v3.25.0.1
Segment Reporting - Summary of Operating Costs and Expenses (Parenthetical) (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Amortization expense $ 254 $ 1,719 $ 1,716
Depreciation expense 30 31 84
Research and Development      
Segment Reporting Information [Line Items]      
Share-based payment expense 193 412 1,396
Depreciation expense 18 19 49
General and Administration      
Segment Reporting Information [Line Items]      
Share-based payment expense 170 372 3,362
Depreciation expense 12 12 35
Pfizer Intangible Asset      
Segment Reporting Information [Line Items]      
Amortization expense $ 254    
ACSD Intangible Asset      
Segment Reporting Information [Line Items]      
Amortization expense   $ 1,719 $ 1,716